Related Experiment Video

Updated: Sep 11, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

599

Correction: Case Report: Regenerative hepatic pseudotumor induced by tislelizumab in a lung cancer patient

Wenrui Wang1, Wei Li2, Tianqi Zhang3

  • 1Digestive Diseases Center, Department of Hepatopancreatobiliary Medicine, The Second Hospital, Jilin University, Changchun, China.

Frontiers in Immunology
|August 11, 2025
PubMed

[This corrects the article DOI: 10.3389/fimmu.2025.1565065.].

Keywords:
PD-1 inhibitorshepatic immune toxicityimmune checkpoint inhibitorsimmune-related adverse eventsimmunotherapy complicationsnon-small cell lung cancerregenerative hepatic pseudotumortislelizumab

More Related Videos

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth08:15

A Hepatocellular Cancer Patient-Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth

Published on: February 2, 2024

968
The Influence of Liver Resection on Intrahepatic Tumor Growth07:55

The Influence of Liver Resection on Intrahepatic Tumor Growth

Published on: April 9, 2016

9.5K

Related Concept Videos